{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:01:25Z","timestamp":1764856885616,"version":"3.46.0"},"reference-count":70,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which ocular involvement represents a clinically significant yet frequently underrecognized contributor to morbidity. Ocular manifestations in SLE may arise from disease activity itself, but also as adverse effects of long-term pharmacological therapy. With the advent of targeted immunomodulatory agents, the therapeutic landscape of SLE has expanded beyond conventional drugs such as hydroxychloroquine and corticosteroids toward biologics and small molecules designed to interfere with specific immunological pathways. These advances have improved systemic disease control and survival; however, their ophthalmological safety profiles remain only partially defined. This review synthesizes current evidence on ocular adverse events associated with both traditional and emerging SLE therapies. Established agents, particularly hydroxychloroquine and corticosteroids, are consistently linked to complications including retinopathy, posterior subcapsular cataracts, steroid-induced glaucoma, and central serous chorioretinopathy. In contrast, recently approved or investigational therapies\u2014such as belimumab, anifrolumab, voclosporin, dual BAFF\/APRIL inhibitors, rituximab, JAK inhibitors, CD40\/CD40L blockade, CD38 inhibition, and mesenchymal stromal cell-based strategies\u2014have limited but evolving safety data, with potential ocular adverse events spanning inflammatory, vascular, neuro-ophthalmic, and structural domains. Although ocular complications appear infrequent in clinical trials, underdetection in real-world practice and insufficient long-term monitoring may underestimate their true incidence. These findings highlight the need for systematic ophthalmological surveillance in patients receiving immunomodulatory therapies for SLE. Early recognition and timely management of ocular toxicity are crucial to safeguarding visual function and optimizing long-term therapeutic outcomes in this vulnerable patient population.<\/jats:p>","DOI":"10.3390\/ijms262311744","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:53:30Z","timestamp":1764856410000},"page":"11744","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-1803","authenticated-orcid":false,"given":"Wojciech","family":"Lubo\u0144","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medical Sciences, Medical University of Silesia, 40-514 Katowice, Poland"},{"name":"Department of Ophthalmology, Professor K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-3517","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Lubo\u0144","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Professor K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9866-8659","authenticated-orcid":false,"given":"Anna","family":"Aga\u015b-Lange","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Professor K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-9628","authenticated-orcid":false,"given":"Mariola","family":"Dorecka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medical Sciences, Medical University of Silesia, 40-514 Katowice, Poland"},{"name":"Department of Ophthalmology, Professor K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Sammaritano","year":"2024","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Musa, M., Chukwuyem, E., Ojo, O.M., Topah, E.K., Spadea, L., Salati, C., Gagliano, C., and Zeppieri, M. (2024). Unveiling Ocular Manifestations in Systemic Lupus Erythematosus. J. Clin. Med., 13.","DOI":"10.3390\/jcm13041047"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lubo\u0144, W., Lubo\u0144, M., Kotyla, P., and Mrukwa-Kominek, E. (2022). Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012264"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.survophthal.2023.07.008","article-title":"Detection of subclinical microvascular changes in systemic lupus erythematosus using OCTA: A systematic review and meta-analysis","volume":"68","author":"Ferreira","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-024-07236-4","article-title":"The importance of developing reproducible primary endpoints for clinical trials in systemic lupus erythematosus","volume":"44","author":"Yang","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.survophthal.2024.04.007","article-title":"Optical coherence tomography angiography measurements in systemic lupus erythematosus: A systematic review and meta-analysis","volume":"69","author":"Fekrazad","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Meng, L., Wang, Y., Yang, Z., Lin, S., Wang, Y., Chen, H., Zhao, X., and Chen, Y. (2024). Ocular fundus changes and association with systemic conditions in systemic lupus erythematosus. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1395609"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/09612033221131183","article-title":"Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data","volume":"31","author":"Wallace","year":"2022","journal-title":"Lupus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108811","DOI":"10.1016\/j.intimp.2022.108811","article-title":"Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and meta-analysis of randomized controlled trials","volume":"109","author":"Xu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cheng, H., Zhang, X.Y., Yang, H.D., Yu, Z., Yan, C.L., Gao, C., and Wen, H.Y. (2022). Efficacy and safety of belimumab\/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.911730"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2207671","DOI":"10.1080\/0886022X.2023.2207671","article-title":"Efficacy and safety of belimumab therapy in lupus nephritis: A systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e14997","DOI":"10.1111\/1756-185X.14997","article-title":"Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus","volume":"27","author":"Suh","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10067-024-07266-y","article-title":"Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: A real-world, retrospective, observational study","volume":"44","author":"Jin","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chan, J., Walters, G.D., Puri, P., and Jiang, S.H. (2023). Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol., 7.","DOI":"10.1186\/s41927-023-00358-3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: An integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/rheumatology\/keac491","article-title":"Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: A post hoc analysis of the TULIP-1 and TULIP-2 trials","volume":"62","author":"Bruce","year":"2023","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, Z., Cheng, R., and Liu, Y. (2022). Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.996662"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active SLE","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomized trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/acr2.11414","article-title":"Interferon inhibition for lupus with anifrolumab: Critical appraisal of the evidence leading to FDA approval","volume":"4","author":"Loncharich","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e000910","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: Results from second-year extension of a randomized phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/acr2.11338","article-title":"Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial","volume":"3","author":"Rubio","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2215\/CJN.0000000000000297","article-title":"Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria","volume":"19","author":"Hodge","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2290365","DOI":"10.1080\/0886022X.2023.2290365","article-title":"The efficacy of immunosuppressive drugs induction therapy for lupus nephritis: A systematic review and network meta-analysis","volume":"45","author":"Dong","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wang, Z., Lang, Y., Liu, X., Wang, Y., and Shao, L. (2025). Post-marketing safety surveillance of voclosporin: An observational, pharmacovigilance study leveraging FAERS database. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1506760"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1744666X.2021.1967747","article-title":"Voclosporin: A novel calcineurin inhibitor for the management of lupus nephritis","volume":"17","year":"2021","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: Results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: A real-life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gao, S., Yang, C., Huang, B., Yang, L., Lu, L., Yang, H., Li, T., and Pan, Q. (2025). Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: A systematic review and meta-analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1472292"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/09612033251332052","article-title":"Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study","volume":"34","author":"Zhang","year":"2025","journal-title":"Lupus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ajo.2012.09.025","article-title":"Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice","volume":"155","author":"Browning","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ophtha.2015.02.011","article-title":"Hydroxychloroquine and chloroquine retinopathy: A systematic review evaluating the multifocal electroretinogram as a screening test","volume":"122","author":"Sang","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ajo.2019.04.025","article-title":"The diagnostic utility of multifocal electroretinography in detecting chloroquine and hydroxychloroquine retinal toxicity","volume":"206","author":"Tsang","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15122","DOI":"10.1097\/MD.0000000000015122","article-title":"Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study","volume":"98","author":"Yen","year":"2019","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00417-025-06772-2","article-title":"Adaptive optics cone arrangement in hydroxychloroquine users without signs of retinal toxicity","volume":"263","author":"Braga","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_43","first-page":"e105","article-title":"Prevalence and risk factors of corticosteroid-induced cataract and glaucoma","volume":"94","author":"Kassumeh","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"ref_44","first-page":"135","article-title":"Statistical attributes of the steroid hypertensive response in the clinically normal eye","volume":"2","author":"Armaly","year":"1963","journal-title":"Invest. Ophthalmol."},{"key":"ref_45","first-page":"163","article-title":"Corticosteroid-induced ocular hypertension and glaucoma: A brief review and update of the literature","volume":"17","author":"Jones","year":"2006","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ophtha.2003.09.024","article-title":"Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: A case-control study","volume":"111","author":"Haimovici","year":"2004","journal-title":"Ophthalmology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/1756-185X.12463","article-title":"Current role of rituximab in systemic lupus erythematosus","volume":"18","author":"Mok","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind phase II\/III EXPLORER trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The LUNAR study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00277-014-2296-5","article-title":"Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine","volume":"94","author":"Chan","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/jcph.1278","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases","volume":"58","author":"Schwabe","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: The dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Abu El-Asrar, A.M., Nawaz, M.I., Ahmad, A., Dillemans, L., Siddiquei, M., Allegaert, E., Gikandi, P.W., De Hertogh, G., Opdenakker, G., and Struyf, S. (2023). CD40 Ligand-CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115582"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: Prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_57","first-page":"1210","article-title":"Efficacy and safety of baricitinib in patients with systemic lupus erythematosus: Results of two phase 3 randomized, controlled trials","volume":"73","author":"Furie","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in patients with rheumatoid arthritis: Results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_60","first-page":"2151","article-title":"Efficacy and safety of deucravacitinib, an oral selective TYK2 inhibitor, in moderate to severe plaque psoriasis: Results from two randomized controlled trials","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"ref_61","first-page":"103324","article-title":"Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial","volume":"70","author":"Ranjbar","year":"2022","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e000704","DOI":"10.1136\/lupus-2022-000704","article-title":"Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE","volume":"9","author":"Kamen","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s10238-023-01132-y","article-title":"Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: A systematic review and network meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e001112","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: Clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1007\/s11033-023-08692-y","article-title":"NAD+ metabolism and eye diseases: Current status and future directions","volume":"50","author":"Liu","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_66","unstructured":"Cakir, B., Cakir, Z., and Dinc, E. (2019). CD38 contributes to neurodegeneration in the retina through NAD+ depletion and oxidative stress pathways. Front. Cell. Neurosci., 13."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e005557","DOI":"10.1136\/rmdopen-2025-005557","article-title":"Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: A randomised, double-blind, placebo-controlled, phase II study","volume":"11","author":"Shen","year":"2025","journal-title":"RMD Open"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaophthalmol.2014.1720","article-title":"Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users","volume":"132","author":"Nika","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.revmed.2006.03.006","article-title":"Central serous chorioretinopathy and systemic diseases: Report of 2 cases associated with corticotherapy","volume":"27","author":"Bouyon","year":"2006","journal-title":"La Rev. De M\u00e9decine Interne"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/sjopt.sjopt_153_23","article-title":"Applications of artificial intelligence-assisted retinal imaging in systemic diseases: A literature review","volume":"37","year":"2023","journal-title":"Saudi J. Ophthalmol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11744\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:58:34Z","timestamp":1764856714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":70,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311744"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311744","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}